NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, announced that independent analyst Robert LeBoyer of Noble Capital Markets has initiated research coverage with an “Outperform” rating and a $6.00 price target. The report reviews the company’s lead programs, including its broad-spectrum antiviral candidate NV-387, along with longer-term development initiatives. NanoViricides noted that while it provided publicly available information and answered technical questions, the analyst independently developed all estimates, financial models and projections.
Separately, the company announced that President and Executive Chairman Anil R. Diwan participated in a “Fireside Chat” published by StockInvestor Daily’s IPO-Edge program, where he discussed NanoViricides’ antiviral technology platform, the potential of NV-387 against multiple viral diseases and variants, the company’s regulatory progress, including FDA Orphan Drug Designation and its Rare Pediatric Disease Designation filing for measles, as well as the resurgence of infectious diseases such as measles, mpox and Ebola. To view the full press release, visit https://ibn.fm/7XBbY.
NanoViricides is a clinical stage company creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is a broad-spectrum antiviral drug being developed as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections and Measles. The company also has NV-HHV-1 for treating Shingles. NanoViricides is currently focused on advancing NV-387 into Phase II human clinical trials.
The company’s platform technology is based on the TheraCour® nanomedicine technology licensed from TheraCour Pharma, Inc. NanoViricides holds a worldwide exclusive perpetual license for several drugs targeting specific human viral diseases, including HIV/AIDS, Hepatitis B and C, Rabies, Herpes Simplex Virus, Varicella-Zoster Virus, Influenza, Dengue, Japanese Encephalitis, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The company intends to obtain licenses for RSV, Poxviruses, and Enteroviruses if initial research is successful.
The initiation of coverage by Noble Capital Markets underscores the potential of NanoViricides’ antiviral technology platform. The $6.00 price target reflects optimism about the company's pipeline, particularly NV-387, which has shown promise as a broad-spectrum antiviral. The analyst report and the Fireside Chat highlight the company's regulatory achievements, including FDA Orphan Drug Designation and the Rare Pediatric Disease Designation filing for measles, which could provide significant market advantages and development incentives.
Investors can find the latest news and updates on NNVC in the company’s newsroom at https://ibn.fm/NNVC. The coverage initiation and positive rating may increase investor attention on NanoViricides as it progresses its lead candidates toward clinical trials.
